Nyxoah's long-term outlook is anchored on the global commercial expansion of its proprietary Genio neurostimulation system, designed to treat obstructive sleep apnea. As clinical adoption grows following regulatory approvals in major markets like the United States and Europe, the company aims to capture a significant share of the multi-billion-dollar sleep disorder medical device market. Long-term projections rely on scaling commercial sales teams, securing broader insurance reimbursement codes, and advancing next-generation product iterations to solidify its competitive positioning against alternative therapies.